FDA places hold on Gilead­'s stud­ies of HIV treat­ment pill com­bo

The FDA or­dered Gilead to pause stud­ies of two long-act­ing HIV pills af­ter “a sub­set of par­tic­i­pants” ex­pe­ri­enced de­creas­es in their im­mune cell counts, which …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER